These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 10600088

  • 1. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB.
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK, Kuti JL, Nicolau DP.
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
    Ambrose PG, Bhavnani SM, Jones RN.
    Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
    [Abstract] [Full Text] [Related]

  • 6. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F.
    Crit Care; 2010 May; 14(4):R126. PubMed ID: 20594297
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S, Kuti JL, Nicolau DP.
    Surg Infect (Larchmt); 2005 May; 6(3):297-304. PubMed ID: 16201939
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS, Frei CR.
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [Abstract] [Full Text] [Related]

  • 10. Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
    Frei CR, Hampton SL, Burgess DS.
    Clin Ther; 2006 Jul; 28(7):1035-40. PubMed ID: 16990081
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 16. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ, Wang H, China Nosocomial Pathogens Resistance Surveillance Study Group.
    Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):375-81. PubMed ID: 12820912
    [Abstract] [Full Text] [Related]

  • 17. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ, Leonard SN, Vilay AM, Mercier RC.
    Clin Ther; 2014 Oct 01; 36(10):1334-44. PubMed ID: 25066667
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS, Waldrep T.
    Clin Ther; 2002 Jul 01; 24(7):1090-104. PubMed ID: 12182254
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
    Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA.
    Antimicrob Agents Chemother; 1997 Nov 01; 41(11):2511-7. PubMed ID: 9371358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.